Galectin Therapeutics (GALT) Other Working Capital Changes (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Other Working Capital Changes of -$140000.0 in Q1 2026, down 129.23% quarter-over-quarter from $479000.0 in Q4 2025, and up 35.48% on a YoY basis from -$103333.3 in Q1 2025.
Galectin Therapeutics (GALT) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Other Working Capital Changes history runs 17 years deep, the most recent figure standing at -$140000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 35.48% year-over-year to -$140000.0; the TTM figure through Mar 2026 stood at -$339000.0 (down 3490.0% YoY), while the FY2025 annual figure was -$416000.0, down 607.32% from the prior year.
- Other Working Capital Changes was -$140000.0 for Q1 2026 at Galectin Therapeutics, down from $479000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $801000.0 in Q4 2023 to a low of -$467000.0 in Q3 2025.
- Historically, Other Working Capital Changes has averaged -$28529.4 across 5 years, with a median of -$183000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes jumped 67.19% in 2024, then slumped 462.65% in 2025.
- A 5-year view of Other Working Capital Changes shows it stood at $671000.0 in 2022, then increased by 19.37% to $801000.0 in 2023, then tumbled by 34.33% to $526000.0 in 2024, then dropped by 8.94% to $479000.0 in 2025, then tumbled by 129.23% to -$140000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$140000.0 (Q1 2026), $479000.0 (Q4 2025), and -$467000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140,000.00 |
| Mar 31, 2026 | -140,000.00 |
| Dec 31, 2025 | 479,000.00 |
| Dec 31, 2025 | 479,000.00 |
| Sep 30, 2025 | -467,000.00 |
| Sep 30, 2025 | -467,000.00 |
| Jun 30, 2025 | -211,000.00 |
| Jun 30, 2025 | -211,000.00 |
| Mar 31, 2025 | -217,000.00 |
| Mar 31, 2025 | -217,000.00 |
| Dec 31, 2024 | 526,000.00 |
| Dec 31, 2024 | 526,000.00 |
| Sep 30, 2024 | -83,000.00 |
| Sep 30, 2024 | -83,000.00 |
| Jun 30, 2024 | -216,000.00 |
| Jun 30, 2024 | -216,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Dec 31, 2023 | 801,000.00 |
| Dec 31, 2023 | 801,000.00 |